Standout Papers

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, p... 2021 2026 2022 2024157
  1. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (2021)
    Kenneth B. Gordon, Peter Foley et al. The Lancet

Immediate Impact

54 standout
Sub-graph 1 of 23

Citing Papers

Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
2024 Standout
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 Standout
4 intermediate papers

Works of Katy White being referenced

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
2021 Standout

Author Peers

Author Last Decade Papers Cites
Katy White 173 49 94 172 13 407
Jennifer Hughes 50 20 109 111 8 412
Emanuela Zagni 55 98 35 18 16 397
D Golan 158 84 10 37 12 345
Susan Gabriel 31 85 41 56 10 378
V. L. Beckett 35 27 57 20 12 336
Kuo‐You Huang 22 12 29 28 22 351
David Hägg 219 46 109 9 17 417
J.D. Pearson 18 19 14 161 12 348
Netta Shoenfeld 40 63 14 49 18 377
C. Davoli 93 166 13 17 22 423

All Works

Loading papers...

Rankless by CCL
2026